BioCardia Analyst Ratings
BioCardia Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/24/2023 | 741.12% | HC Wainwright & Co. | $9 → $9 | Reiterates | Buy → Buy |
| 06/21/2023 | 741.12% | HC Wainwright & Co. | → $9 | Reiterates | Buy → Buy |
| 05/11/2023 | 741.12% | HC Wainwright & Co. | → $9 | Reiterates | Buy → Buy |
| 03/30/2023 | 741.12% | HC Wainwright & Co. | → $9 | Reiterates | → Buy |
| 11/11/2022 | — | Dawson James | Downgrades | Buy → Neutral | |
| 12/20/2021 | 741.12% | HC Wainwright & Co. | → $9 | Initiates Coverage On | → Buy |
| 04/16/2021 | — | Dawson James | Downgrades | Buy → Neutral | |
| 09/21/2020 | 974.77% | Alliance Global Partners | → $11.5 | Initiates Coverage On | → Buy |
| 11/26/2019 | 1956.07% | Brookline Capital | → $22 | Initiates Coverage On | → Buy |
| 10/10/2019 | 741.12% | Maxim Group | → $9 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 2023 年 7 月 24 日 | 741.12% | HC Wainwright & Co. | 9 美元 → 9 美元 | 重申 | 購買 → 購買 |
| 06/21/2023 | 741.12% | HC Wainwright & Co. | → 9 美元 | 重申 | 購買 → 購買 |
| 05/11/2023 | 741.12% | HC Wainwright & Co. | → 9 美元 | 重申 | 購買 → 購買 |
| 03/30/2023 | 741.12% | HC Wainwright & Co. | → 9 美元 | 重申 | → 購買 |
| 11/11/2022 | — | 道森·詹姆斯 | 降級 | 買入 → 中性 | |
| 2021 年 12 月 20 日 | 741.12% | HC Wainwright & Co. | → 9 美元 | 啓動覆蓋開啓 | → 購買 |
| 2021 年 4 月 16 日 | — | 道森·詹姆斯 | 降級 | 買入 → 中性 | |
| 2020 年 9 月 21 日 | 974.77% | 聯盟全球合作伙伴 | → 11.5 美元 | 啓動覆蓋開啓 | → 購買 |
| 11/26/2019 | 1956.07% | 布魯克林資本 | → 22 美元 | 啓動覆蓋開啓 | → 購買 |
| 10/10/2019 | 741.12% | Maxim 集團 | → 9 美元 | 啓動覆蓋開啓 | → 購買 |
What is the target price for BioCardia (BCDA)?
BioCardia（BCDA）的目標價格是多少？
The latest price target for BioCardia (NASDAQ: BCDA) was reported by HC Wainwright & Co. on July 24, 2023. The analyst firm set a price target for $9.00 expecting BCDA to rise to within 12 months (a possible 741.12% upside). 5 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2023年7月24日公佈了BioCardia（納斯達克股票代碼：BCDA）的最新目標股價。這家分析公司將目標股價定爲9.00美元，預計BCDA將在12個月內升至9美元（可能上漲741.12％）。去年有5家分析公司公佈了評級。
What is the most recent analyst rating for BioCardia (BCDA)?
分析師對BioCardia（BCDA）的最新評級是多少？
The latest analyst rating for BioCardia (NASDAQ: BCDA) was provided by HC Wainwright & Co., and BioCardia reiterated their buy rating.
BioCardia（納斯達克股票代碼：BCDA）的最新分析師評級由HC Wainwright & Co. 提供，BioCardia重申了他們的買入評級。
When is the next analyst rating going to be posted or updated for BioCardia (BCDA)?
BioCardia（BCDA）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioCardia, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioCardia was filed on July 24, 2023 so you should expect the next rating to be made available sometime around July 24, 2024.
分析師在進行了廣泛的研究（包括瀏覽公開財務報表、與BioCardia的高管和客戶交談以及聽取財報電話會議）後得出了股票評級。大多數分析師每三個月進行一次評級，因此每家公司每年應該獲得4個評級。BioCardia的最後一次評級是在2023年7月24日提交的，因此您應該預計下一個評級將在2024年7月24日左右公佈。
Is the Analyst Rating BioCardia (BCDA) correct?
分析師對 BioCardia (BCDA) 的評級正確嗎？
While ratings are subjective and will change, the latest BioCardia (BCDA) rating was a reiterated with a price target of $9.00 to $9.00. The current price BioCardia (BCDA) is trading at is $1.07, which is out of the analyst's predicted range.
雖然評級是主觀的，會發生變化，但最新的BioCardia（BCDA）評級得到了重申，目標股價爲9.00美元至9.00美元。BioCardia（BCDA）目前的交易價格爲1.07美元，超出了分析師的預測區間。